Merrimack Pharmaceuticals Story

Merrimack Pharmaceuticals Inc -- USA Stock  

USD 11.29  0.08  0.71%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 7.73% .

Similar stores for Merrimack Pharmaceuticals

Analysts See -0.28 EPS for Merrimack Pharmaceuticals,
Frisco FastballFull coverage
over two weeks ago at 
Analyst Consensus to Hold Signal Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. stock price moved with surging change along with the volume 0.2 million shares in Friday trading session.
over a month ago at 
Merrimack Pharmaceuticals Inc. Plunges 6.06 percent on January 08
Equities News - Jan 8, 2018 Merrimack Pharmaceuticals Inc. had a rough trading day for Monday January 08 as shares tumbled 6.06, or a loss of -0.67 per share, to close at 10.39.

Did you try this?

Run My Watchlist Analysis Now

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Hide  View All  NextLaunch My Watchlist Analysis

Cash and Equivalents

Cash and Equivalents Comparative Analysis
  Cash and Equivalents 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in cash and equivalents category among related companies. Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.